Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

Market report includes a comprehensive understanding of current treatment practices, emerging HER2+ gastric cancer therapies, market share of individual therapies, and current and forecasted HER2+ ...

HER2-positive breast cancer was reported to transform from luminal progenitor and mature luminal cells (Lim et al., 2009; Prat and Perou, 2009; Tharmapalan et al., 2019). The tumorigenesis of ...

Phase 1 1 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors.

For patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, the oral proteolysis-targeting chimera estrogen receptor degrader, vepdegestrant ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with metastatic HER2-positive breast cancer," said Sara Tolaney, MD, MPH, of the Dana ...

The current first-line treatment for people with locally advanced or metastatic HER2-positive breast cancer is a taxane given in combination with the HER2-targeted therapy drugs trastuzumab ...

About 15% to 20% of breast cancers are HER2-positive and for decades now have been treated by Herceptin, Perjeta and other treatments that home in on the protein. Enhertu is one of the newest — and ...

For more than a decade, the first-line standard of care for locally advanced or metastatic HER2-positive breast cancer has been a taxane given with trastuzumab (Herceptin; Genentech) and ...